biapenem (L 627)

structure given in first source

Also Known As:

L 627; 3-((6,7-dihydro-5H-pyrazolo(1,2-a)(1,2,4)triazol-4-ium-6-yl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3,2,0)hept-2-ene-2-carboxylate; CLI 86,815; CLI 86815; CLI-86815; L-627; LJC 10627; LJC-10627; LJC10,627; 5H-Pyrazolo(1,2-a)(1,2,4)triazol-4-ium, 6-((2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)thio)-6,7-dihydro-, hydroxide, inner salt, (4R-(4alpha,5beta,6beta(R*)))-

Networked: 84 relevant articles (18 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ikawa, Kazuro: 6 articles (02/2013 - 02/2008)
2.	Morikawa, Norifumi: 6 articles (02/2013 - 02/2008)
3.	Kohno, Shigeru: 4 articles (09/2013 - 01/2008)
4.	Ikeda, Kayo: 4 articles (12/2011 - 02/2008)
5.	Izumikawa, Koichi: 3 articles (09/2013 - 01/2008)
6.	Yanagihara, Katsunori: 3 articles (09/2013 - 01/2008)
7.	Bae, Jong-Sup: 2 articles (06/2021 - 02/2020)
8.	Baek, Moon-Chang: 2 articles (06/2021 - 02/2020)
9.	Griffith, David C: 2 articles (03/2021 - 10/2020)
10.	Amoh, Takashi: 2 articles (01/2017 - 01/2017)

Related Diseases

1.	Infections 12/01/1994 - "3. The results above indicate that L-627 is useful for the treatment of general infections in pediatrics." 01/01/2016 - "The aim of this study is to evaluate the efficacy and safety of biapenem for the treatment of infection diseases. " 06/01/1998 - "Biapenem is in phase III trials in Germany, South Africa, Spain, Australia and New Zealand for skin infections, and phase I trials in the UK and the US." 12/01/1994 - "[Studies on the efficacy and safety of biapenem (L-627) against infections in pediatrics]." 09/01/1992 - "These results suggest that L-627 merits further study in the treatment of infections caused by a wide range of pathogens."
2.	Intraabdominal Infections 01/01/1996 - "The present study shows that biapenem may be useful in the treatment of intra-abdominal infections." 02/01/1995 - "Biapenem seems to be useful in the treatment of intraabdominal infections." 10/01/2008 - "Thus, these results should support the clinical use of biapenem as a treatment for intra-abdominal infections and facilitate the design of the dosing regimen." 01/01/1992 - "Efficacy of L-627, a new carbapenem, in the treatment of experimentally induced intra-abdominal infections in rats." 03/01/1999 - "One trial has been published comparing biapenem with imipenem/cilastatin for treatment of intraabdominal infections. "
3.	Pneumonia (Pneumonitis) 06/01/2014 - "The results of this study confirmed the efficacy and safety of 300 mg of biapenem administered thrice daily for the treatment of pneumonia in elderly patients." 02/01/2013 - "Therefore, the purpose of this study was evaluating the efficacy and safety of biapenem against pneumonia in the elderly and its pharmacokinetics. " 02/01/2013 - "Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics." 06/01/2014 - "The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly." 02/01/2013 - "Although biapenem is used in the treatment of pneumonia, the clinical data on elderly patients are yet insufficient. "
4.	Communicable Diseases (Infectious Diseases) 07/01/1994 - "From these results, it has been concluded that L-627 is a safe and effective drug to be used in treatment of pediatric infectious diseases." 07/01/1994 - "The results indicate that L-627 is effective and safe in children with acute infectious diseases and suggest the usefulness of L-627 in the pediatric field." 01/01/2016 - "Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials." 11/01/1999 - "[Clinical evaluation of biapenem in various infectious diseases]." 07/01/1994 - "L-627 was administered intravenously to 11 patients with ages ranging 2 months to 10 years and 5 months with acute infectious diseases. "
5.	Urinary Tract Infections (Urinary Tract Infection) 01/01/2010 - "A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections." 12/01/2013 - "This multicenter, randomized, parallel-controlled clinical trial was conducted to compare the clinical efficacy, bacterial eradication rates and safety of biapenem and meropenem in the treatment of bacterial lower respiratory tract infections and urinary tract infections (UTIs) at nine centres in China. " 12/01/1994 - "1. L-627 at dose levels of 5.4 mg/kg to 12.4 mg/kg (daily doses of 16.2 mg/kg to 37.2 mg/kg) was administered by intravenous drip infusion 3 times daily for 5 to 7 days to 2 cases of pneumonia, 3 cases of skin and soft-tissue infections and 1 case of urinary tract infection for a total of 6 cases. " 01/01/2002 - "In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections. " 07/01/1994 - "Those patients who responded well to L-627 treatment included 11 children with pneumonia, 1 with scarlet fever, 1 with cervical lymphadenitis, 2 with cellulitis, 6 with urinary tract infection. "

Related Drugs and Biologics

1.	Imipenem
2.	Imipenem Drug Combination Cilastatin (Primaxin)
3.	Carbapenems (Carbapenem Antibiotics)
4.	Meropenem (Merrem)
5.	Ceftazidime (Fortum)
6.	Penicillins (Penicillin)
7.	mevastatin (CS 500)
8.	Penicillin-Binding Proteins (Penicillin-Binding Protein)
9.	Cytokines
10.	Cilastatin

Related Therapies and Procedures

1.	Continuous Renal Replacement Therapy
2.	Intravenous Administration
3.	Critical Care (Surgical Intensive Care)
4.	Intravenous Infusions
5.	Therapeutics